標靶癌症治療的進展
Advancements in Targeted Cancer Therapies
標靶癌症治療的進步已在腫瘤學領域引發了一場革命，將重心從廣譜化學治療轉向精準醫學。
Advancements in targeted cancer therapy have sparked a revolution in oncology, shifting the focus from broad-spectrum chemotherapy to precision medicine.
不同於影響所有快速分裂細胞的傳統療法，標靶治療透過利用癌細胞獨特的遺傳或蛋白質層面的弱點，精確地識別並阻斷癌細胞。
Unlike traditional treatments that affect all rapidly dividing cells, targeted therapies specifically identify and disable cancer cells by exploiting their unique genetic or protein-based vulnerabilities.
現代治療通常被歸類為能進入細胞的小分子抑制劑，或是與細胞表面標靶結合的單株抗體。
Modern treatments are typically categorized as small-molecule inhibitors, which can enter cells, or monoclonal antibodies that bind to surface targets.
儘管這些療法相較於傳統選項通常產生較少的全身性副作用，但它們面臨著嚴峻的挑戰，包括後天抗藥性的發展以及高昂的生物標記檢測需求。
While these therapies often cause fewer systemic side effects than conventional options, they face significant hurdles, including the development of acquired resistance and the necessity for costly biomarker testing.
然而，該領域仍在快速演進。
Nevertheless, the field continues to evolve rapidly.
人工智慧在藥物開發中的整合以及不限組織類型治療法的出現，正為更有效、個人化的護理鋪路。
The integration of artificial intelligence in drug discovery and the emergence of tissue-agnostic treatments are paving the way for more effective, personalized care.
透過針對特定的癌症驅動因子，科學正將過去難以處理的疾病轉化為可控的病況，極大地改善了全球患者的生活品質。
By targeting specific drivers of cancer, science is turning once-intractable diseases into manageable conditions, drastically improving the quality of life for patients worldwide.
